Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF-Reference-Cited by-同舟云学术

Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF

Published:2015-06 Issue:3 Volume:13 Page:e191-e198
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Aggarwal Rahul R.,Beer Tomasz M.,Weinberg Vivian K.,Higano Celestia,Taplin Mary-Ellen,Ryan Charles J.,Lin Amy M.,Alumkal Joshi,Graff Julie N.,Nordquist Luke T.,Herrera Isheen,Small Eric J.

Funder

Sanofi

Department of Defense/Prostate Cancer Clinical Trials Consortium

Prostate Cancer Foundation

Genzyme

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference25 articles.

1. Cancer statistics, 2013;Siegel;CA Cancer J Clin,2013

2. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004